The bill
A bill to amend title 5, United States Code, to require disclosure of conflicts of interest with respect to rulemaking, and for other purposes.
S. 3210, 119th Congress β read as touching Pharmaceuticals.
Sponsored by
Sen. Warren, Elizabeth [D-MA]
ID: W000817
Follow the money
The bill
S. 3210, 119th Congress β read as touching Pharmaceuticals.
The sponsor
Every bill has someone who introduced it. That name is where the paper trail starts.
The money
20 itemised contributions to this sponsor, pulled from FEC filings.
Track this bill's progress through the legislative process
Latest Action
Invalid Date
π Current Status
Next: The bill will be reviewed by relevant committees who will debate, amend, and vote on it.
1. Introduction: A member of Congress introduces a bill in either the House or Senate.
2. Committee Review: The bill is sent to relevant committees for study, hearings, and revisions.
3. Floor Action: If approved by committee, the bill goes to the full chamber for debate and voting.
4. Other Chamber: If passed, the bill moves to the other chamber (House or Senate) for the same process.
5. Conference: If both chambers pass different versions, a conference committee reconciles the differences.
6. Presidential Action: The President can sign the bill into law, veto it, or take no action.
7. Became Law: If signed (or if Congress overrides a veto), the bill becomes law!
No summary available
Sen. Warren, Elizabeth [D-MA]
Congress 119 β’ 2024 Election Cycle
No PAC contributions found
No organization contributions found
No committee contributions found
Hub layout: Politicians in center, donors arranged by type in rings around them.
Showing 21 nodes and 20 connections (38 secondary connections hidden)
Total contributions: $76,000
Showing top 12 donors by contribution amount
Which industries are materially affected by specific provisions in this bill. 4 helped.
Section 18(b) requires agencies to take into account distributional effects and social equity impact of a rule when issuing such rule, which could benefit pharmaceutical companies by ensuring regulations consider equitable access to medicines and health outcomes, particularly for protected classes.
Section 18(b)'s focus on distributional effects and social equity impact could help hospitals and health systems by promoting regulations that address health disparities and improve access to care for underserved populations, aligning with their mission and potential funding incentives.
Section 18(b)'s requirement to consider distributional effects and social equity impact could benefit health insurers by encouraging regulations that promote equitable coverage and reduce disparities, potentially expanding market access and stabilizing risk pools.
Section 18(b)'s emphasis on distributional effects and social equity impact could help long-term care providers by supporting regulations that address inequities in access to nursing home and home health services, particularly for elderly and disabled populations in protected classes.
For each industry this bill affects, here's what the sponsor (Sen. Warren, Elizabeth [D-MA])received from donors associated with that industry during the 2022βpresent cycles. Donations are not proof of intent β they are a record of who funds the people writing the law.
Anti-Racism in Public Health Act of 2025
119/s/1489
A bill to prevent corruption by appropriately limiting donations for any public property, building, or fixture at the White House, the Naval Observatory, or certain other public property, for events on such property, or for monuments to living current or former Presidents, current or former Vice Presidents, or current or former employees or officers appointed by the President.
119/s/3191